

Anthera Pharmaceuticals Inc
 Form 4
 April 05, 2010

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
HENNEY CHRISTOPHER S

(Last) (First) (Middle)

C/O ANTHERA
 PHARMACEUTICALS,
 INC., 25801 INDUSTRIAL
 BOULEVARD, SUITE B

(Street)

HAYWARD, CA 94545

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
**Anthera Pharmaceuticals Inc
 [ANTH]**

3. Date of Earliest Transaction
 (Month/Day/Year)
04/01/2010

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner
 Officer (give title below) Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/01/2010		M		5,841	A	\$ 0.26
Common Stock	04/01/2010		M		29,205 (1)	A	\$ 1.34
Common Stock	04/01/2010		M		5,841 (2)	A	\$ 1.51

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Amount or Number of Shares
Stock Option (right to buy)	\$ 0.26	04/01/2010		M	5,841	⁽³⁾ 03/13/2017	Common Stock	5,841
Stock Option (right to buy)	\$ 1.34	04/01/2010		M	29,205	⁽⁴⁾ 06/26/2018	Common Stock	29,205
Stock Option (right to buy)	\$ 1.51	04/01/2010		M	5,841	⁽⁵⁾ 02/18/2019	Common Stock	5,841

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
HENNEY CHRISTOPHER S C/O ANTERA PHARMACEUTICALS, INC. 25801 INDUSTRIAL BOULEVARD, SUITE B HAYWARD, CA 94545	X			

Signatures

/s/ Mitzi Chang, by power of attorney for Christopher S. Henney,
Ph.D. 04/05/2010

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) A portion of the shares is subject to a right of repurchase held by the Issuer, which lapses according to the following vesting schedule: in equal monthly installments over a four-year period beginning from the April 23, 2008 vesting start date (the "Vesting Start Date"). The shares are completely vested on the fourth anniversary of the Vesting Start Date.

(2) A portion of the shares is subject to a right of repurchase held by the Issuer, which lapses according to the following vesting schedule: in equal monthly installments over a four-year period beginning from the August 12, 2008 vesting start date (the "Vesting Start Date"). The shares are completely vested on the fourth anniversary of the Vesting Start Date.

(3) 100% of the shares subject to this Stock Option are immediately exercisable. However, all unvested shares underlying this Stock Option are subject to a right of repurchase held by the Issuer, which will lapse according to the following vesting schedule: in equal monthly installments over a one-year period beginning from the March 13, 2007 vesting start date (the "Vesting Start Date"). This Stock Option is completely vested on the first anniversary of the Vesting Start Date.

(4) 100% of the shares subject to this Stock Option are immediately exercisable. However, all unvested shares underlying this Stock Option are subject to a right of repurchase held by the Issuer, which will lapse according to the following vesting schedule: in equal monthly installments over a four-year period beginning from the April 23, 2008 vesting start date (the "Vesting Start Date"). This Stock Option is completely vested on the fourth anniversary of the Vesting Start Date.

(5) 100% of the shares subject to this Stock Option are immediately exercisable. However, all unvested shares underlying this Stock Option are subject to a right of repurchase held by the Issuer, which will lapse according to the following vesting schedule: in equal monthly installments over a four-year period beginning from the August 12, 2008 vesting start date (the "Vesting Start Date"). This Stock Option is completely vested on the fourth anniversary of the Vesting Start Date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.